RT Conference Proceedings
T1 An ex vivo native environment precision medicine test shows high clinical correlation with responses to first line acute myeloid leukemia treatment
A1 Montesinos, P
A1 Ballesteros, J
A1 Martinez Cuadron, D
A1 Martinez Lopez, J
A1 Serrano, J
A1 Perez de Oteyza, J
A1 Fernandez, P
A1 Rodriguez Macias, G
A1 Vidriales, B
A1 Herrera, P
A1 Tormo, M
A1 Bergua, J
A1 Garcia, R
A1 Vives, S
A1 Fernandez, MA
A1 Lavilla, E
A1 Jimenez, S
A1 Perez Simon, JA
A1 Simiele, A
A1 Gonzalez, A
A1 Gonzalez, B
A1 Burgaleta, C
A1 Lopez, JA
A1 Bethancourt, C
A1 Bautista, G
A1 Alonso, A
A1 Colorado, M
A1 Sierra, J
A1 Navas, B
A1 Hernandez Rivas, JA
A1 Vera, JA
A1 Amador, L
A1 Cordoba, R
A1 de la Fuente, A
A1 Ramos, F
A1 Cervero, CJ
A1 Rayon, C
A1 Salamero, O
A1 Marti, E
A1 Loez, A
A1 Olave, T
A1 Gaspar, M
A1 Gorrochategui, J
A1 Rojas, JL
A1 Gomez, C
A1 Hernandez, P
A1 Robles, A
A1 Ortega, I
A1 Villoria, J
A1 Moscardo, F
A1 Troconiz, I
A1 Sanz, MA
K1 Adulto
K1 Médula ósea
K1 Citarabina
K1 Ambiente
K1 Humanos
K1 Idarrubicina
K1 Quimioterapia de inducción
K1 Mantenimiento
AB This novel test is able to predict the clinical response to Ida+Ara-C induction with overall correlation and predictive values of 80%, higher than ever achieved. Considering this result and current clinical responserate of 66.7% (70% in this study), clear clinical benefits can be achieved withthe use of the test. Adding the cytogenetic risk profile further increase the correlationto 90%. Thus this novel test may be valuable information to guide 1st line patient therapy
PB Ferrata Storti Foundation
SN 0390-6078
YR 2016
FD 2016-06
LK http://hdl.handle.net/10668/2442
UL http://hdl.handle.net/10668/2442
LA en
NO Montesinos P, Ballesteros J, Martinez Cuadron D. Martinez Lopez J, Serrano J, Perez de Oteyza J et al. An ex vivo native environment precision medicine test shows high clinical correlation with responses to first line acute myeloid leukemia treatment. Haematologica. 2016; 101 (s1) P569
DS RISalud
RD Apr 6, 2025